Takeda Pharmaceutical Company Limited Acquires Maverick Therapeutics, Inc.

Otsuka Pharmaceutical Acquires Jnana Therapeutics

August 1, 2024

Biotechnology

Otsuka Pharmaceutical Co., Ltd. will acquire clinical-stage biotech Jnana Therapeutics, making it a wholly owned subsidiary via Otsuka America, Inc. The deal values Jnana at $800 million in upfront cash plus up to $325 million in development and regulatory milestones and is intended to add Jnana's RAPID chemoproteomics platform and lead program JNT-517 (a potential oral PKU therapy) to Otsuka's specialty and autoimmune pipeline.

Takeda Acquires Nimbus Therapeutics' TYK2 Program Subsidiary (Nimbus Lakshmi)

February 8, 2023

Pharmaceuticals

Takeda Pharmaceutical Company Limited has completed the acquisition of all shares of Nimbus Lakshmi, Inc. (the TYK2 program subsidiary of Nimbus Therapeutics) for approximately $4.0 billion upfront, with up to $2.0 billion in potential milestone payments. The deal adds TAK-279 (NDI-034858), a selective oral TYK2 inhibitor moving into late‑stage development, strengthening Takeda's late‑stage pipeline in immune‑mediated diseases including psoriasis and other immunological indications.

Takeda to Acquire Adaptate Biotherapeutics to Expand γδ T Cell Engager Platform for Solid Tumors

January 10, 2022

Biotechnology

Takeda Pharmaceutical Company has exercised its option to acquire Adaptate Biotherapeutics, a UK immunotherapy company developing antibody-based therapeutics that modulate Vδ1 gamma delta (γδ) T cells. The acquisition will add Adaptate’s antibody-based γδ T cell engager platform, including pre-clinical candidates and discovery pipeline programs, to Takeda’s immuno-oncology portfolio.

Takeda Pharmaceutical to Acquire GammaDelta Therapeutics

October 27, 2021

Biotechnology

Takeda exercised its option to acquire GammaDelta Therapeutics Limited, gaining its allogeneic gamma-delta (γδ) T cell therapy platforms and early-stage cell therapy programs. The acquisition is expected to be finalized in Q1 of Takeda’s fiscal year 2022, subject to antitrust review (including HSR).

Amgen Acquires Teneobio for $900M with Up to $1.6B in Milestones

July 27, 2021

Biotechnology

Amgen agreed to acquire clinical-stage biotechnology company Teneobio for $900 million in upfront cash plus potential contingent milestone payments up to $1.6 billion. The acquisition adds Teneobio's heavy-chain antibody discovery platform, bispecific/multispecific antibody technologies and a Phase 1 T-cell engager (TNB-585), strengthening Amgen's antibody research capabilities and oncology pipeline.

Merck Acquires Pandion Therapeutics

February 25, 2021

Biotechnology

Merck will acquire Pandion Therapeutics for $60 per share in cash, representing an approximate total equity value of $1.85 billion, via a tender offer and subsequent merger. Pandion is a clinical-stage biotechnology company focused on precision immune modulators (TALON platform) with lead candidate PT101 targeting regulatory T cells for autoimmune diseases; the transaction is expected to close in the first half of 2021 subject to customary conditions.